What if reducing the buildup of senescent cells meant helping the body remove them, rather than designing a drug to kill them directly?
A new study in Nature Aging points toward that possibility. Researchers found that a selective cellular recycling pathway helps both senescent cells and the immune cells responsible for clearing them. When this pathway falters, the two can become caught in a cycle that favours persistence of senescent cells.
Activating the pathway with an experimental compound, CA77.1, reduced senescent-cell burden and some fibrosis-related changes in aged mice. It also reduced disease severity in a separate mouse model of lung fibrosis. These are preclinical findings, not evidence that the compound slows human aging or extends life.
The paper, published October 5, 2026, is by Rebecca Sereda, Kristen Lindenau, Antonio Diaz and colleagues, with Ana Maria Cuervo as corresponding author.
Why senescent cells can become a problem
Cellular senescence is a response to stress or damage in which cells stop dividing but remain alive and metabolically active. It can serve useful purposes, including limiting the growth of damaged cells and helping coordinate tissue repair.
The problem is persistence. Senescent cells can release proteins and other molecules that affect surrounding tissue. This mixture is called the senescence-associated secretory phenotype, or SASP. Depending on the context, it can encourage inflammation, tissue remodelling and senescence in neighbouring cells.
Immune cells normally help remove senescent cells. With age, changes in the cells themselves and in immune surveillance can make clearance less effective. The new research investigates one contributor to that failure, rather than claiming to explain every reason senescent cells accumulate.
CMA is a selective protein-cleanup system
Autophagy refers to processes through which cells deliver their own components to lysosomes, compartments containing enzymes that break material down. This supports recycling and cellular quality control.
Chaperone-mediated autophagy, or CMA, is a particularly selective version. A helper protein called HSC70 recognises a targeting sequence in certain proteins and brings them to a receptor called LAMP2A on the lysosome. The selected proteins are unfolded and transported across the membrane for degradation.
Think of CMA as a controlled service entrance for individual proteins. It does not swallow an entire senescent cell. That larger cleanup task involves immune cells, including macrophages, which can engulf cells and cellular remains.
Because CMA regulates which proteins remain inside a cell, its decline can affect metabolism, secretion and immune function as well as the disposal of damaged proteins.
What the researchers did
The team combined cell-culture experiments, genetic mouse models, aging experiments and analysis of human lung tissue. They compared fibroblasts, cells that help maintain connective tissue, from young and aged mice, and disrupted LAMP2A to investigate what happens when CMA is impaired.
Much of the laboratory work induced senescence with palbociclib. Some experiments used other triggers. The researchers measured CMA activity with fluorescent reporters and examined changes in cellular proteins, metabolites and secreted molecules.
They also studied mouse bone marrow-derived macrophages and mice with LAMP2A deletion driven by LysM-Cre, a genetic tool targeting myeloid immune cells. This let them test whether impaired cleanup in immune cells contributes to senescent-cell persistence.
A failure on both sides of the clearance process
Young fibroblasts increased CMA activity after senescence induction. Aged fibroblasts had lower baseline activity and failed to mount the same response. Blocking CMA in young cells reproduced several features of the aged-cell response.
Importantly, CMA loss alone did not cause full conventional senescence: the cells could still proliferate until a senescence-inducing stimulus was applied. Instead, impaired CMA changed how cells responded and what they secreted.
Secretions from CMA-deficient cells promoted senescence-related changes in neighbouring fibroblasts and interfered with macrophage function. Macrophages with impaired CMA were less effective at engulfing material and clearing dying cells. Senescent fibroblasts persisted more readily in co-cultures with those macrophages.
One mechanistic link involved the CD47-SIRPα signalling system, sometimes described as a “do not eat me” signal. CMA impairment disrupted internalisation and lysosomal turnover of the macrophage receptor SIRPα, helping sustain an inhibitory signal against engulfment.
In mice, disrupting CMA in these immune cells increased senescence-related tissue changes and delayed wound healing. Results differed by tissue and sex, so the effect was not uniform throughout the body.
What CA77.1 changed in aged mice
CA77.1 is an experimental small molecule that activates CMA. The researchers administered it to mice beginning at 18 months of age and assessed tissues after five months, alongside vehicle-treated aged mice and young controls. The Methods describe oral treatment in gelatin pellets at 30 milligrams per kilogram of body weight, five days per week.
Treated mice had less age-associated accumulation of cells positive for senescence-associated beta-galactosidase in gonadal white fat, liver and lung, in both sexes. Several senescence- and inflammation-related gene readouts also shifted favourably. Fibrosis, or scar-like connective-tissue deposition, was reduced more clearly in white fat, with some reduction in the liver.
Separately, treating macrophages isolated from old mice for 48 hours restored their bead-engulfing activity toward levels seen in young-mouse macrophages. That supports a contribution from improved immune clearance, but systemic treatment could act on several cell types.
These measurements do not show that every harmful senescent cell was removed. Nor was this a lifespan-extension experiment.
A separate test in lung fibrosis
The researchers used bleomycin, a drug that can injure the lungs, to produce pulmonary fibrosis in young male mice. This is a model of lung injury and scarring, not the same condition as longstanding human idiopathic pulmonary fibrosis, or IPF.
CA77.1 treatment began either two days or seven days after bleomycin exposure. Earlier treatment better preserved body weight, an indirect measure of disease severity, and reduced lung scarring and several fibrosis, senescence and inflammation readouts. Starting later was less effective.
The timing matters. Protection during an early inflammatory phase does not establish that CMA activation can reverse established fibrosis in patients. The study also found that a lower gene-based CMA score after bleomycin did not necessarily mean lower measured CMA activity in lung fibroblasts, illustrating why molecular proxies need careful interpretation.
How this differs from senolytic drugs
Conventional senolytics aim to selectively kill susceptible senescent cells, often by interfering with mechanisms that keep them alive. Dasatinib plus quercetin is one much-studied example.
The approach here centres on restoring a pathway involved in cellular protein handling and immune clearance. The proposed benefit comes partly from enabling macrophages to do their cleanup work more effectively and altering the signals produced by senescent cells.
That does not mean senescent cells survive indefinitely or that removal happens without cell death. It means the experimental intervention targets a biological clearance mechanism rather than using direct senescent-cell killing as its central strategy. The paper does not establish that this approach is safer or more effective than senolytics.
Human relevance, without a human treatment result
Human lung analyses offered a reason to investigate further. Gene-expression-based CMA scores were lower in IPF lung datasets. Lysosomes isolated from IPF lung samples also showed reduced protein uptake in a laboratory CMA assay and lower levels of LAMP2, consistent with impaired function of the pathway. The lysosomal experiments used samples from four controls and four patients with IPF.
This is tissue evidence, not a clinical trial. It cannot establish whether impaired CMA causes human IPF, results from the disease, or participates in a feedback loop. No patients in this study received CA77.1.
What remains unknown
The authors identify several limits. Fibroblasts were the main cellular model, and most senescence experiments used one inducing drug. LysM-Cre can affect monocytes and granulocytes as well as macrophages, so the mouse genetic results cannot be attributed exclusively to macrophages. Human findings remain correlative.
Senescence markers also require interpretation. No single marker identifies all senescent cells, and CMA directly changes protein turnover and lysosomal biology. The combination of measurements strengthens the evidence, but changes in markers are not automatically proof of complete cellular clearance or clinical benefit.
Next steps include testing other cell types and disease settings, separating the contributions of immune and senescent cells, and determining whether benefits persist after treatment ends. Researchers also need to establish dosing, long-term safety and effects on useful senescence responses before drawing conclusions about human treatment.
The compound is patented, and the paper discloses relevant author commercial interests. Independent replication will be valuable alongside further mechanistic work.
A different question for senescence research
The study connects two processes that are often discussed separately: declining intracellular protein cleanup and declining immune removal of senescent cells. Its contribution is a testable explanation for why those cells persist, plus evidence that activating CMA can improve several outcomes in mice.
The next question is whether restoring this system can produce a durable, safe benefit in human disease. For now, the research supports further investigation of biological clearance, without establishing an anti-aging treatment for people.
Primary research and further reading
Sereda, R., Lindenau, K., Diaz, A. and colleagues. Decline of chaperone-mediated autophagy in aging impairs macrophage clearance of senescent cells. Nature Aging, published October 5, 2026. DOI: 10.1038/s43587-026-01240-w. Main findings: Figures 1, 3-7; limitations and treatment details: Discussion and Methods.
For the broader clinical context, see our analysis: Whatever Happened to Senolytics?